JP2013503184A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503184A5
JP2013503184A5 JP2012527002A JP2012527002A JP2013503184A5 JP 2013503184 A5 JP2013503184 A5 JP 2013503184A5 JP 2012527002 A JP2012527002 A JP 2012527002A JP 2012527002 A JP2012527002 A JP 2012527002A JP 2013503184 A5 JP2013503184 A5 JP 2013503184A5
Authority
JP
Japan
Prior art keywords
seq
cancer
antibody
antigen
mip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012527002A
Other languages
English (en)
Japanese (ja)
Other versions
JP5740772B2 (ja
JP2013503184A (ja
Filing date
Publication date
Priority claimed from US12/644,146 external-priority patent/US7981398B2/en
Priority claimed from US12/731,781 external-priority patent/US8003111B2/en
Priority claimed from US12/752,649 external-priority patent/US8034352B2/en
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed filed Critical
Priority claimed from PCT/US2010/046889 external-priority patent/WO2011025904A1/en
Publication of JP2013503184A publication Critical patent/JP2013503184A/ja
Publication of JP2013503184A5 publication Critical patent/JP2013503184A5/ja
Publication of JP5740772B2 publication Critical patent/JP5740772B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012527002A 2009-08-31 2010-08-27 二重特異性免疫サイトカインドック−アンド−ロック（ｄｎｌ）複合体及びその治療的使用 Active JP5740772B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US23842409P 2009-08-31 2009-08-31
US61/238,424 2009-08-31
US12/644,146 2009-12-22
US12/644,146 US7981398B2 (en) 2005-04-06 2009-12-22 PEGylation by the dock and lock (DNL) technique
US12/731,781 US8003111B2 (en) 2005-04-06 2010-03-25 Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US12/731,781 2010-03-25
US12/752,649 2010-04-01
US12/752,649 US8034352B2 (en) 2005-04-06 2010-04-01 Tetrameric cytokines with improved biological activity
US12/754,140 2010-04-05
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US12/754,740 2010-04-06
PCT/US2010/046889 WO2011025904A1 (en) 2009-08-31 2010-08-27 Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015080993A Division JP5999217B2 (ja) 2009-08-31 2015-04-10 二重特異性免疫サイトカインドック−アンド−ロック（ｄｎｌ）複合体及びその治療的使用

Publications (3)

Publication Number Publication Date
JP2013503184A JP2013503184A (ja) 2013-01-31
JP2013503184A5 true JP2013503184A5 (https=) 2013-09-19
JP5740772B2 JP5740772B2 (ja) 2015-07-01

Family

ID=43628394

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012527002A Active JP5740772B2 (ja) 2009-08-31 2010-08-27 二重特異性免疫サイトカインドック−アンド−ロック（ｄｎｌ）複合体及びその治療的使用
JP2015080993A Active JP5999217B2 (ja) 2009-08-31 2015-04-10 二重特異性免疫サイトカインドック−アンド−ロック（ｄｎｌ）複合体及びその治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015080993A Active JP5999217B2 (ja) 2009-08-31 2015-04-10 二重特異性免疫サイトカインドック−アンド−ロック（ｄｎｌ）複合体及びその治療的使用

Country Status (7)

Country Link
EP (1) EP2473186A4 (https=)
JP (2) JP5740772B2 (https=)
CN (1) CN102481348A (https=)
AU (1) AU2010286642B2 (https=)
CA (1) CA2772572A1 (https=)
IN (1) IN2012DN01331A (https=)
WO (1) WO2011025904A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
CN102596235A (zh) * 2009-08-31 2012-07-18 免疫医疗公司 显示有效细胞毒活性的包含豹蛙酶(rap)的免疫毒素的组合物和使用方法
CA2794499A1 (en) * 2010-04-01 2011-10-06 Immumomedics, Inc. Antibody-based depletion of antigen-presenting cells and dendritic cells
WO2013112801A1 (en) * 2012-01-26 2013-08-01 Ibc Pharmaceuticals, Inc. Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
ES2645431T3 (es) * 2012-07-06 2017-12-05 Innovative Technologies In Biological Systems S.L. Polipéptido de fusión fluorescente, biosensor que comprende dicho polipéptido y usos de los mismos
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) * 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
CN114920848B (zh) * 2015-05-13 2024-10-11 埃博灵克斯股份有限公司 基于cd3反应性的t细胞募集多肽
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
KR20180091097A (ko) * 2015-12-23 2018-08-14 그리노파티온 바이오테크 게엠베하 보체 활성화를 억제하기 위한 폴리펩티드
CN116769054A (zh) * 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2019241483A1 (en) * 2018-06-13 2019-12-19 The Scripps Research Institute Nanoparticle vaccines with novel structural components
US20230242655A1 (en) * 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
WO2003093296A2 (en) * 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
CA2497254A1 (en) * 2002-09-06 2004-03-18 Forschungsverbund Berlin E. V. Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same
ES2665422T3 (es) * 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
CA2607056C (en) * 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
SG153825A1 (en) * 2005-12-16 2009-07-29 Ibc Pharmaceuticals Inc Multivalent immunoglobulin-based bioactive assemblies
WO2007134037A2 (en) * 2006-05-15 2007-11-22 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments

Similar Documents

Publication Publication Date Title
JP2013503184A5 (https=)
JP2016513098A5 (https=)
US10385139B2 (en) Murine, chimeric, humanized or human anti-TNF-alpha antibodies
US8282934B2 (en) Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
EP2271364B1 (en) Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
FI3903829T3 (fi) Solunsisäisesti katkeavan sidoksen omaavia immunokonjugaatteja
US9498542B2 (en) Tetrameric cytokines with improved biological activity
AU2013302696B2 (en) T-cell redirecting bispecific antibodies for treatment of disease
AU2010286642B2 (en) Bispecific immunocytokine dock-and-lock (DNL) complexes and therapeutic use thereof
JP2016520548A5 (https=)
JP2014514345A5 (https=)
US20110020273A1 (en) Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
JP2016534092A5 (https=)
US9931413B2 (en) Tetrameric cytokines with improved biological activity
CN105566498A (zh) 双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途